CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Orilissa (elagolix)

Last Updated: February 18, 2020
Result type: Reports
Product Line: Reimbursement Review

Generic Name: elagolix

Brand Name: Orilissa

Manufacturer: AbbVie Corporation

Indications: Moderate to severe pain associated with endometriosis

Submission Type: Non-submission

Project Status: Not filed

Recommendation Type: CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer